Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 6/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951264 | 0.92 | PDE9A (0.38) | ACHEPDE9AMETAP1HTR1ADRD2 | |
| SCHEMBL8169501 | 0.90 | ACHE (0.37) | ACHEPDE9ASLC6A2METAP1HTR1A | |
| SCHEMBL5951441 | 0.90 | ACHE (0.45) | ACHEMETAP1HTR1ADRD2HTR2A | |
| SCHEMBL5951443 | 0.87 | METAP1 (0.39) | ACHEMETAP1EDNRBEDNRA | |
| SCHEMBL5952782 | 0.86 | ACHE (0.41) | ACHESLC6A2METAP1HTR1ADRD2 | |
| SCHEMBL5953020 | 0.81 | METAP1 (0.42) | ACHEMETAP1HTR1ADRD2HTR2A | |
| SCHEMBL8161364 | 0.81 | ACHE (0.39) | ACHEMETAP1HTR1ADRD2HTR7 | |
| SCHEMBL5952184 | 0.80 | HTR1A (0.39) | ACHEMETAP1HTR1ADRD2HTR7 | |
| SCHEMBL8169500 | 0.79 | ACHE (0.30) | ACHE | |
| SCHEMBL5951507 | 0.79 | ACHE (0.43) | ACHEMETAP1HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-0968158-B1 | METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM | BASELL POLYOLEFINE GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | ACHE 839/4885PDE9A 3041/4885SLC6A2 4252/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | ACHE 820/4885PDE9A 3232/4885SLC6A2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.